Table 3 Association between SSRI prescription and breast cancer recurrence within strata of (a) Group I, women with tumours that expressed the oestrogen receptor and who received at least 1 year of tamoxifen therapy (ERP+/TAM+) or (b) Group II, women with tumours that did not express the oestrogen receptor, who never received tamoxifen therapy, and who survived at least 1 year after diagnosis (ERP−/TAM−)

From: Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram

Citalopram prescription

Cases/controls

Crude OR (95% CI)

Adjusted OR (95% CI) a

(a) Group I: ERP+/TAM+

 Never user

167/163

1.0 (reference)

1.0 (reference)

 Ever user

17/21

0.79 (0.40, 1.6)

0.85 (0.42, 1.7)

Intermittent use

10/14

0.69 (0.30,1.6)

0.72 (0.30, 1.7)

Regular use

7/7

0.97 (0.34, 2.8)

1.1 (0.37, 3.3)

(b) Group II: ERP−/TAM−

 Never user

84/82

1.0 (reference)

1.0 (reference)

 Ever user

3/5

0.60 (0.14, 2.5)

0.78 (0.17, 3.6)

  1. aAdjusted for age category and other CYP2D6-inhibiting medications (see the Supplementary online material for a complete list of these medications and the frequency of their use in the study population).
Back to article page